AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6125636 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard medication)
Number of subjects: 90
Study 31868978 — intervention group
Group type: EXPERIMENTAL
Intervention: PM-AM-PM group (n = 13)
Number of subjects: 26
Study 31868978 — intervention group
Group type: COMPARATOR
Intervention: AM-PM-AM group (n = 13)
Number of subjects: 26
Study 30723183 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic emphysema
Number of subjects: 16624
Study 30723183 — intervention group
Group type: COMPARATOR
Intervention: No radiographic emphysema
Number of subjects: 16624
Study 28402208 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic scheduling procedure
Number of subjects: 0
Study 28402208 — intervention group
Group type: COMPARATOR
Intervention: Randomly assigned appointments
Number of subjects: 0
Study 28402208 — intervention group
Group type: COMPARATOR
Intervention: Uniformly assigned appointments
Number of subjects: 0
Study 27494089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab plus chlorambucil (oral chlorambucil 10 mg/m2 on Days 1-7 of a 28-day cycle; ofatumumab: Cycle 1: 300 mg on Day 1 and 1000 mg on Day 8; subsequent cycles: 1000 mg Day 1 for 3-12 cycles)
Number of subjects: 0
Study 27494089 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil monotherapy (oral chlorambucil 10 mg/m2 on Days 1-7 of a 28-day cycle)
Number of subjects: 0
Study 24120714 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone 2.5 mg
Number of subjects: 60
Study 24120714 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone 5 mg
Number of subjects: 60
Study 24120714 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone 7.5 mg
Number of subjects: 60
Study 24120714 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone 10 mg
Number of subjects: 60
Study 24120714 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone 15 mg
Number of subjects: 60
Study 24120714 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH stimulation tests
Number of subjects: 60
Study 24120714 — intervention group
Group type: EXPERIMENTAL
Intervention: metyrapone test
Number of subjects: 60
Study 24120714 — intervention group
Group type: EXPERIMENTAL
Intervention: markers of bone turnover
Number of subjects: 60
Study 22688509 — intervention group
Group type: EXPERIMENTAL
Intervention: LAM+ADV
Number of subjects: 27
Study 22688509 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV
Number of subjects: 27
Study 22688509 — intervention group
Group type: COMPARATOR
Intervention: ADV
Number of subjects: 27
Study 19898642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control (HbA(1c) < 6%) in ACCORD trial
Number of subjects: 0
Study 19898642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control in general (ACCORD, ADVANCE, VADT, UKPDS post-trial)
Number of subjects: 0
Study 19898642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 0
Study 19898642 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 0
Study 19898642 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term glycemic control (UKPDS post-trial)
Number of subjects: 0
Study 17572346 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1% solution (N = 134)
Number of subjects: 282
Study 17572346 — intervention group
Group type: COMPARATOR
Intervention: Patching (N = 148)
Number of subjects: 282
Study 17572346 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine only (n = 41)
Number of subjects: 282
Study 17572346 — intervention group
Group type: COMPARATOR
Intervention: Patching only (n = 64)
Number of subjects: 282
Study 14747205 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adiponectin levels in boys aged 15-18 years
Number of subjects: 500
Study 14747205 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma adiponectin levels in girls aged 11-14 years
Number of subjects: 500
Study 14747205 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone levels in boys
Number of subjects: 500
Study 14747205 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin resistance and beta-cell function
Number of subjects: 500
Study 14747205 — intervention group
Group type: EXPERIMENTAL
Intervention: Adiponectin levels during puberty in boys
Number of subjects: 500
Study 11446314 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-36 m
Number of subjects: 300
Study 11446314 — intervention group
Group type: COMPARATOR
Intervention: SF-36
Number of subjects: 300
Study 9509783 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel‐sided bars (rigid joint)
Number of subjects: 0
Study 9509783 — intervention group
Group type: EXPERIMENTAL
Intervention: Oval straight bars (resilient joint)
Number of subjects: 0
Study 9509783 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 7578765 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem 500 mg IV every 8 hours
Number of subjects: 235
Study 7578765 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/cilastatin 500 mg IV every 6 hours
Number of subjects: 235
Study 2595265 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery with a 3:1 ratio
Number of subjects: 36
Study 2595265 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery with a 1:3 ratio
Number of subjects: 36
Study 2595265 — intervention group
Group type: COMPARATOR
Intervention: Unoperated group
Number of subjects: 36
Study 1101611 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine 1% with adrenaline 5 mug/ml
Number of subjects: 0
Study 1101611 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5% with adrenaline 5 mug/ml
Number of subjects: 0
Study 31062079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea catechin-enriched beverage (611 mg catechins, 88 mg caffeine)
Number of subjects: 30
Study 31062079 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (0 mg catechins, 81 mg caffeine)
Number of subjects: 30
Study 30662324 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (ETV) monotherapy
Number of subjects: 360
Study 30662324 — intervention group
Group type: COMPARATOR
Intervention: LAM and ADV combination therapy (Control)
Number of subjects: 360
Study 29223429 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservatively managed non-infarct-related artery lesions
Number of subjects: 664
Study 29223429 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model based on clinical and angiographic characteristics
Number of subjects: 664
Study 26341167 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical Baseball Cards (SBCs)
Number of subjects: 162
Study 26341167 — intervention group
Group type: COMPARATOR
Intervention: Control (no SBCs)
Number of subjects: 162
Study 26341167 — intervention group
Group type: EXPERIMENTAL
Intervention: SBCs
Number of subjects: 162
Study 24185842 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular plus resistance training protocol (CRT)
Number of subjects: 75
Study 24185842 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity strength training protocol (HIST)
Number of subjects: 75
Study 24185842 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 75
Study 20570319 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin (NFT) prophylaxis 100 mg b.i.d. for 7 days preoperatively
Number of subjects: 101
Study 20570319 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative antibiotic prophylaxis
Number of subjects: 101
Study 19917943 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stitch length (<10 mm from the wound edge)
Number of subjects: 737
Study 19917943 — intervention group
Group type: COMPARATOR
Intervention: Long stitch length
Number of subjects: 737
Study 16476929 — intervention group
Group type: EXPERIMENTAL
Intervention: DCA (25 mg/kg/day)
Number of subjects: 30
Study 16476929 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12756868 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 10
Study 11083552 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human PDGF-BB (rhPDGF-BB)
Number of subjects: 28
Study 11083552 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 28
Study 9279344 — intervention group
Group type: EXPERIMENTAL
Intervention: TUT-7 (menogaril) at 75 or 100 mg/body/day for 7 or 14 days with two-week drug withdrawal
Number of subjects: 165
Study 9279344 — intervention group
Group type: EXPERIMENTAL
Intervention: TUT-7 (menogaril)
Number of subjects: 165
Study 8443037 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72394 (MAO‐A inhibitor) 16 mg
Number of subjects: 9
Study 8443037 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 72974A (MAO‐B inhibitor) 12 mg
Number of subjects: 9
Study 31288610 — intervention group
Group type: EXPERIMENTAL
Intervention: Witnesses of childhood violence
Number of subjects: 907
Study 31288610 — intervention group
Group type: EXPERIMENTAL
Intervention: Female witnesses
Number of subjects: 907
Study 31288610 — intervention group
Group type: EXPERIMENTAL
Intervention: Male witnesses
Number of subjects: 907
Study 31288610 — intervention group
Group type: COMPARATOR
Intervention: Non-witnesses
Number of subjects: 907
Study 28814150 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 186
Study 28814150 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 186
Study 27793175 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminor® paclitaxel‐coated drug‐eluting balloon (DEB) catheter
Number of subjects: 172
Study 27793175 — intervention group
Group type: COMPARATOR
Intervention: Noncoated, plain old balloon angioplasty (POBA) catheter
Number of subjects: 172
Study 24322377 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 (GS) combination chemotherapy
Number of subjects: 101
Study 24322377 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine (GEM)
Number of subjects: 101
Study 22283861 — intervention group
Group type: COMPARATOR
Intervention: T lymphocytes (CD3+) expression of glucocorticoid receptors (GCR) in late responders (LR)
Number of subjects: 60
Study 22283861 — intervention group
Group type: COMPARATOR
Intervention: T lymphocytes (CD3+) expression of glucocorticoid receptors (GCR) in early responders (ER)
Number of subjects: 60
Study 22283861 — intervention group
Group type: EXPERIMENTAL
Intervention: T lymphocytes (CD3+) expression of glucocorticoid receptors (GCR)
Number of subjects: 60
Study 20334686 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention (diet, physical activity, behavioral therapy)
Number of subjects: 324
Study 20334686 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight loss intervention
Number of subjects: 324
Study 18674465 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.5 mg/kg body weight)
Number of subjects: 20
Study 18674465 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5,000 units)
Number of subjects: 20
Study 18674465 — intervention group
Group type: COMPARATOR
Intervention: Control (UFH)
Number of subjects: 20
Study 16171631 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosaic-type osteochondral autologous transplantation (OAT)
Number of subjects: 60
Study 16171631 — intervention group
Group type: COMPARATOR
Intervention: Microfracture (MF)
Number of subjects: 60
Study 12134175 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 months antiepileptic drug therapy
Number of subjects: 73
Study 12134175 — intervention group
Group type: COMPARATOR
Intervention: 2 years antiepileptic drug therapy
Number of subjects: 73
Study 10212074 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 200 IU/kg of body weight/day up to a maximum of 400 IU/day
Number of subjects: 39
Study 10212074 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D 960 IU/day
Number of subjects: 39
Study 7995773 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant interferon gamma (r IFN-gamma) at doses of 0.1, 0.2, 0.6, 1.8, or 5.4 mg
Number of subjects: 8
Study 7995773 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled recombinant interferon gamma (r IFN-gamma)
Number of subjects: 8
Study 2186320 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (40 mg/m2) + Cyclophosphamide (600 mg/m2)
Number of subjects: 224
Study 2186320 — intervention group
Group type: EXPERIMENTAL
Intervention: Epirubicin (40 mg/m2) + Cyclophosphamide (600 mg/m2)
Number of subjects: 224
Study 2186320 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (12 mg/m2) + Cyclophosphamide (600 mg/m2)
Number of subjects: 224
Study 2186320 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone
Number of subjects: 224
Study 2186320 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 224
Study 2186320 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin
Number of subjects: 224
Study 2186320 — intervention group
Group type: COMPARATOR
Intervention: Patients with more than one organ site involved
Number of subjects: 224
Study 2186320 — intervention group
Group type: COMPARATOR
Intervention: Patients who had previously received adjuvant chemotherapy
Number of subjects: 224
Study 406624 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana low dose with aversive noise
Number of subjects: 96
Study 406624 — intervention group
Group type: COMPARATOR
Intervention: Marijuana low dose without aversive noise
Number of subjects: 96
Study 406624 — intervention group
Group type: EXPERIMENTAL
Intervention: Marijuana high dose with aversive noise
Number of subjects: 96
Study 406624 — intervention group
Group type: COMPARATOR
Intervention: Marijuana high dose without aversive noise
Number of subjects: 96
Study 406624 — intervention group
Group type: COMPARATOR
Intervention: Coltsfoot
Number of subjects: 96
Study 406624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 31337400 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMGb)
Number of subjects: 12
Study 31337400 — intervention group
Group type: COMPARATOR
Intervention: Joint torque biofeedback (Rb)
Number of subjects: 12
Study 31337400 — intervention group
Group type: EXPERIMENTAL
Intervention: Lokomat training (both biofeedback types)
Number of subjects: 12
Study 28528567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) consisting of 12 individual sessions with a psychologist over 16 weeks
Number of subjects: 91
Study 28528567 — intervention group
Group type: COMPARATOR
Intervention: Control treatment consisting of three consultations with an MS nurse over 16 weeks
Number of subjects: 91
Study 25539660 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 145
Study 25539660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 23329565 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 23329565 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation in AGA infants
Number of subjects: 0
Study 23329565 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21472469 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel surgery with tonsillectomy
Number of subjects: 144
Study 21472469 — intervention group
Group type: COMPARATOR
Intervention: Multilevel surgery without tonsillectomy
Number of subjects: 144
Study 21472469 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative AHI, BMI, age as predictors
Number of subjects: 144
Study 21472469 — intervention group
Group type: EXPERIMENTAL
Intervention: Success according to Sher criteria
Number of subjects: 144
Study 19757514 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 l polyethylene glycol (group A)
Number of subjects: 201
Study 19757514 — intervention group
Group type: COMPARATOR
Intervention: 4 l polyethylene glycol (group B)
Number of subjects: 201
Study 19757514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 201
Study 16964276 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach placement (5-week block)
Number of subjects: 49
Study 16964276 — intervention group
Group type: COMPARATOR
Intervention: Traditional hospital-based training
Number of subjects: 49
Study 15455188 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day
Number of subjects: 164
Study 15455188 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to risedronate)
Number of subjects: 164
Study 11178303 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB using the Octopus II stabilizing system
Number of subjects: 26
Study 11178303 — intervention group
Group type: COMPARATOR
Intervention: Conventional CABG with CPB
Number of subjects: 26
Study 9306147 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress MIBI SPECT imaging
Number of subjects: 235
Study 8294198 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 14
Study 8294198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2963034 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine (200 mg/day orally)
Number of subjects: 22
Study 2963034 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg/day orally)
Number of subjects: 22
Study 2963034 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (40 mg/day orally)
Number of subjects: 22
Study 31872245 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 g daily of icosapent ethyl
Number of subjects: 8179
Study 31872245 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy (control)
Number of subjects: 8179
Study 29486741 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive Home Treatment (IHT)
Number of subjects: 0
Study 29486741 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (CAU)
Number of subjects: 0
Study 27411773 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered CPR education (PCE)
Number of subjects: 54
Study 27411773 — intervention group
Group type: COMPARATOR
Intervention: Control group (video-based CPR self-education and booklets)
Number of subjects: 54
Study 24647395 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 continuous portions (2C)
Number of subjects: 65
Study 24647395 — intervention group
Group type: COMPARATOR
Intervention: 2 intermittent portions (2I)
Number of subjects: 65
Study 22947291 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-flap epi-LASIK with mitomycin C (MMC)
Number of subjects: 18
Study 22947291 — intervention group
Group type: COMPARATOR
Intervention: On-flap epi-LASIK with mitomycin C (MMC)
Number of subjects: 18
Study 20922865 — intervention group
Group type: EXPERIMENTAL
Intervention: Male patients
Number of subjects: 80
Study 20922865 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower preoperative hemoglobin levels
Number of subjects: 80
Study 20922865 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 80
Study 20922865 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with longer duration of surgery
Number of subjects: 80
Study 20922865 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall study conclusion
Number of subjects: 80
Study 18696748 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 0
Study 16182714 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoldopam mesylate
Number of subjects: 2
Study 16182714 — intervention group
Group type: COMPARATOR
Intervention: Dopamine
Number of subjects: 2
Study 12619939 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 40 microg
Number of subjects: 101
Study 12619939 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide 20 microg
Number of subjects: 101
Study 12619939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 10574619 — intervention group
Group type: EXPERIMENTAL
Intervention: rHuIL-10 at a dose of 4 or 8 microg/kg/day as a single daily subcutaneous injection for 28 days
Number of subjects: 16
Study 9064111 — intervention group
Group type: EXPERIMENTAL
Intervention: Orocal 500 mg (one dissolve-in-the-mouth tablet in the morning and one in the evening)
Number of subjects: 22
Study 9064111 — intervention group
Group type: COMPARATOR
Intervention: Cacit 1000 (one effervescent tablet)
Number of subjects: 22
Study 9064111 — intervention group
Group type: EXPERIMENTAL
Intervention: Orocal 500 mg (two tablets in a single dose)
Number of subjects: 22
Study 9064111 — intervention group
Group type: EXPERIMENTAL
Intervention: Orocal 500 mg (two doses)
Number of subjects: 22
Study 1883790 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth‐EZ chair
Number of subjects: 1250
Study 1883790 — intervention group
Group type: COMPARATOR
Intervention: Conventional delivery bed
Number of subjects: 1250
Study 6847466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild silver protein solution (Argyrol)
Number of subjects: 32
Study 6847466 — intervention group
Group type: COMPARATOR
Intervention: Untreated eye (control)
Number of subjects: 32
Study 30821654 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients (vitamins and minerals)
Number of subjects: 27
Study 30821654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 30821654 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients
Number of subjects: 27
Study 30033681 — intervention group
Group type: EXPERIMENTAL
Intervention: using tissue spreader technique (A)
Number of subjects: 10
Study 30033681 — intervention group
Group type: EXPERIMENTAL
Intervention: using skin hooks technique (B)
Number of subjects: 10
Study 30033681 — intervention group
Group type: EXPERIMENTAL
Intervention: using sharp scissor technique (C)
Number of subjects: 10
Study 28906405 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadripolar leads (QUAD)
Number of subjects: 52
Study 28906405 — intervention group
Group type: COMPARATOR
Intervention: Conventional bipolar leads (CONV)
Number of subjects: 52
Study 26347970 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour transcutaneous tibial nerve stimulation for 6 weeks (total of 12 treatments)
Number of subjects: 43
Study 26347970 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-hour transcutaneous tibial nerve stimulation for 6 weeks (total of 12 treatments)
Number of subjects: 43
Study 24247188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol 100 mg/day
Number of subjects: 74
Study 24247188 — intervention group
Group type: EXPERIMENTAL
Intervention: Pycnogenol 150 mg/day
Number of subjects: 74